一种中国药物在晚期乳腺癌患者的存活率方面有显著改善,目前正在进行快速审查。 A Chinese drug showed significant improvement in survival for advanced breast cancer patients and is under fast review.

Sichuan Kelun-Biotech报告说,在采用CDK4/6抑制剂和化疗的高级荷尔蒙受体阳性、HER2-阴性乳腺癌患者中,其药物抗菌素Tirumotecan(sac-TMT)的药物试验第3阶段取得了积极结果。 Sichuan Kelun-Biotech reported positive Phase 3 trial results for its drug sacituzumab tirumotecan (sac-TMT) in advanced hormone receptor-positive, HER2-negative breast cancer patients who had progressed on CDK4/6 inhibitors and chemotherapy. 该研究在2025年欧洲紧急环境管理组织大会上提出,研究表明,血清-TMT将无累进性存活率中位值提高到8.3个月,而化疗为4.1个月,将疾病累进或死亡风险降低65%。 Presented at the 2025 ESMO Congress, the study showed sac-TMT improved median progression-free survival to 8.3 months versus 4.1 months with chemotherapy, reducing disease progression or death risk by 65%. 中国药物管制机构正在优先审查该药物的这种用途申请。 The drug’s application for this use has been accepted and is under priority review by China’s drug regulator.